Finland vs Palestine, State of: Prevalence rate of hypertension in men aged 30-79
Finland
41
in 2019
Palestine, State of
40.7
in 2019
Finland rank
62nd
Palestine, State of rank
64th
Prevalence rate of hypertension in men aged 30-79 over time
- Finland
- Palestine, State of
How they compare
Finland currently reports 41 against 40.7 in Palestine, State of, a difference of 0.3.
Across all 30 years both countries report, Finland has been ahead every year.
Finland ranks 62nd and Palestine, State of ranks 64th of 195 countries.
Finland has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Finland | Palestine, State of | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 50.48 | 38.38 | 12.1 | Finland |
| 2000s | 45.62 | 40.24 | 5.38 | Finland |
| 2010s | 42.57 | 40.67 | 1.9 | Finland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in men aged 30-79, Finland or Palestine, State of?
- Finland, at 41 against 40.7 in Palestine, State of as of 2019.
- What is the difference in prevalence rate of hypertension in men aged 30-79 between Finland and Palestine, State of?
- 0.3, with Finland ahead.
- How many years of comparable data are there for Finland and Palestine, State of?
- 30 years are reported by both, from 1990 to 2019.
- How do Finland and Palestine, State of rank globally for prevalence rate of hypertension in men aged 30-79?
- Finland ranks 62nd and Palestine, State of ranks 64th of 195 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in men aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of male population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.